Jonathan Riess, MD
Enriched profileProfessor of Medicine (Hematology/Oncology); Director of Thoracic Oncology, UC Davis Comprehensive Cancer Center · UC Davis Comprehensive Cancer Center
Jonathan Riess is Professor of Medicine (Hematology/Oncology); Director of Thoracic Oncology, UC Davis Comprehensive Cancer Center at UC Davis Comprehensive Cancer Center. OpenAlex indexes 538 publications with 14,811 citations (h-index 45); ClinicalTrials.gov lists 12 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Jonathan Riess, M.D., M.S., is Professor of Medicine (Hematology/Oncology) at UC Davis Comprehensive Cancer Center (UC Davis School of Medicine, Division of Hematology/Oncology). The public record shows 538 publications with 14,811 citations (h-index 45), centered on Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, Lung Cancer Research Studies. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 31 companies, 1 NIH-funded awards (2023–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Lung Cancer Treatments and Mutations
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 31 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 17 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 119.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Sponsor: Nuvalent Inc.
Industry payments
Updated 27 Aug 2026
31 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- TAIHO ONCOLOGY, INC.Program year20258 payments
- AstraZeneca Pharmaceuticals LPProgram year202513 payments
- Eli Lilly and CompanyProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
57.5%Kinase inhibitor57.5%Tagrisso47%Alecensa24%Erlotinib Hcl13%Retevmo12%Xalkori5%Part D<11 patientsNervous system
18.1%Phenothiazine10.7%Prochlorperazine Maleate100%Part D≥24 patientsAtypical Antipsychotic4.6%Olanzapine100%Part D≥11 patientsSensory organs
12%Corticosteroid12%Dexamethasone100%Part D≥25 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2023–2026 per NIH RePORTER. The latest:
- University of California and UT Southwestern D-PDTC
University of California at Davis
FY2026$1,041,566U54CA283766 - Characterizing treatment responses for common lung cancer (LC) subtypes in Latinos and Asians
University of California at Davis
FY2026$239,748U54CA283766 - University of California and UT Southwestern D-PDTC
University of California at Davis
FY2026$129,653U54CA283766
Congress activity
Updated 27 Aug 2026
75 congress contributions (2012–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 1264: Limited apoptotic response in RBM10 wild type/deficient EGFR-mutant lung cancer patient-derived models overcome by combined EGFR and BCL-2/BCL-xL inhibition.
AACR Annual Meeting
AACR2026Presenting author - Abstract CT248: Zidesamtinib in patients with ROS1+ NSCLC previously treated with repotrectinib or taletrectinib
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.
Journal of clinical oncology
Article2026 - The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial.
Clinical cancer research
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyArticle1,804 citations2020
- 02Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyArticle1,437 citations2022
- 03
- 04Non–Small Cell Lung Cancer, Version 4.2024Article789 citations2024
- 05siRNA-directed inhibition of HIV-1 infectionArticle777 citations2002
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jonathan-riess-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/jonathan-riess-a1751285
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Jonathan-W-Riess-71314337
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Apple Podcasts
podcasts.apple.com/us/podcast/aacr-2026-highlights-kras-updates/id1462694630
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com ↗ - Other
onclive.com/authors/jonathan-riess-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - X / Twitter
x.com/OncLive/status/1865697837813531104
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →physicians.ucdavis.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →physicians.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗
Editorial & leadership roles
journal and society appointments- Member
NCCN Non-Small Cell Lung Cancer / Malignant Pleural Mesothelioma / Thymomas and Thymic Carcinomas Guidelines Panel
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗ - Director
Phase I Clinical Trials Program, UC Davis Comprehensive Cancer Center (ORCID self-attested current role)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗ - Physician Leader
Lung Cancer Integrated Service Line, UC Davis Comprehensive Cancer Center (ORCID self-attested current role)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →alkpositive.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.